News

New disability benefits in Canada may help MS, other patients

The government of Canada soon will provide new income benefits designed to help Canadians living with a disability — including people with multiple sclerosis (MS). Applauded by MS Canada, a nonprofit that actively advocated for these benefits, the announcement follows the passing of the Canada Disability Benefit Act,…

Stem cell therapy highly effective in active RRMS: Real-world study

Nearly 80% of adults with highly active relapsing-remitting multiple sclerosis (RRMS) were free of relapses or confirmed disability worsening two years after receiving stem cell transplant, according to a real-world study in Denmark. Moreover, more than two-thirds (69%) of these RRMS patients achieved a clinical outcome called NEDA-3, or…

Review: Ocrevus best of 4 antibody therapies for progressive MS

Among four antibody-based therapies for multiple sclerosis (MS), Ocrevus (ocrelizumab) works best to prevent disability progression and other measures of disease activity in people with PPMS, or primary progressive MS, a review study found. However, the medication is associated with an increased risk of infection, data suggested.

Education found to help with MS treatment adherence in Iran

An educational intervention program was found to help improve treatment adherence among people with multiple sclerosis (MS) receiving injectable therapies in a clinical trial in Iran. The program was designed based on the theory of planned behavior — a psychological premise that assumes people act rationally according to their…

GlobeStar, AIP team up to design clinical trials for Project Amethyst

GlobeStar Therapeutics (GSTC) is teaming up with Advanced Innovative Partners (AIP) to design and implement clinical trials of Project Amethyst, an investigational therapy for multiple sclerosis (MS) that aims to reduce neurodegeneration — when nerve cells in the body lose function and ultimately die. The new memorandum of understanding (MOU)…

PoNS device wins accreditation needed to be covered by Medicare

The PoNS device — officially the Portable Neuromodulation Stimulator, designed to help improve walking ability in people with multiple sclerosis (MS) — has been granted the accreditation needed for Medicare and Medicaid coverage in the U.S., according to Helius Medical Technologies, which makes the device. That designation, called…

T-cell changes reflect pregnancy’s protective effects in MS

Changes in the gene activity within immune T-cells explain why women with multiple sclerosis (MS) improve during pregnancy, a study reports. Gene activity changes during and after pregnancy were highly similar between MS patients and healthy women. Many of the genes whose activity was altered during pregnancy were associated…

10 MS nonprofits unite on shared research strategy to find cures

To address knowledge gaps and avoid duplicate efforts in the lab and in trials, 10 multiple sclerosis (MS) organizations from around the world have committed to a single global research strategy to find a cure for the progressive neurodegenerative disorder. The nonprofits, with headquarters in countries ranging from the…

ACROBiosystems joins Diagnostic Biochips for neuroscience research

Aneuro, a brand of the biotechnology company ACROBiosystems, is partnering with the biosensor maker Diagnostic Biochips to help bring to market new approaches to treating disorders such as multiple sclerosis (MS). Specifically, the companies are collaborating to launch electrophysiology solutions that can be used in living…

Blood-clotting protein triggers brain inflammation in MS: Study

A blood-clotting protein called fibrin can activate immune cells in the brain and contribute to inflammation and neurodegeneration in multiple sclerosis (MS), a study revealed. Because blood vessels become leaky in neurodegenerative conditions like MS, the blood can cross into the brain, which is known to activate multiple pro-inflammatory…

Ocrevus appears to be better than rituximab at preventing MS relapses

Ocrevus (ocrelizumab) appears to be more effective than rituximab at reducing relapse activity in people with relapsing-remitting multiple sclerosis (RRMS), but disability progression outcomes are comparable between the therapies, an observational study of patients reported. “Study findings suggest that the effectiveness of rituximab on MS relapses was…